Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526163 | 0.83 | KDM4E (0.33) | KMT2AKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL1028624 | 0.82 | GAA (0.31) | — | |
| SCHEMBL1637707 | 0.79 | ACHE (0.32) | — | |
| SCHEMBL358784 | 0.78 | GAA (0.42) | KDM4EALDH1A1MAPT | |
| SCHEMBL20243478 | 0.78 | MAPT (0.37) | KMT2AKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL27829826 | 0.77 | — | — | |
| SCHEMBL2515959 | 0.77 | NPC1 (0.45) | KDM4EALDH1A1CD44TSHR | |
| SCHEMBL2349664 | 0.77 | HTR2A (0.31) | — | |
| SCHEMBL3989267 | 0.77 | CA2 (0.34) | — | |
| SCHEMBL1969378 | 0.76 | ACHE (0.39) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | claimed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | claimed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1718616-A2 | ISOQUINOLINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082858-A2 | ISOQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| US-5656648-A | TREATMENT OF PATHOLOGIES NECESSITATING STIMULATION OF CHOLECYSTOKININ-A RECEPTORS BY TOTAL OR PARTIAL AGONIST EFFECT | SANOFI (FR) | 1997-08-12 | — | — | US | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0611766-A1 | Polysubstituted 2-amido thiazoles derivatives, process for their preparation, pharmaceutical compositions and utilization for the preparation of a medicament | SANOFI (FR) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | KMT2A 1108/4885KDM4E 1691/4885MEN1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.